<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306757</url>
  </required_header>
  <id_info>
    <org_study_id>1211/2019</org_study_id>
    <nct_id>NCT04306757</nct_id>
  </id_info>
  <brief_title>Flow Controlled Ventilation in Cardiac Surgery</brief_title>
  <official_title>Flow Controlled Ventilation Versus Pressure Controlled Ventilation in Cardiac Surgery After Cardiopulmonary Bypass Without Ventilation - a Prospective, Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates effects of individualized (by compliance guided pressure settings)
      flow-controlled ventilation compared to best clinical practice pressure controlled
      ventilation in cardiac surgery requiring cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to investigate flow-controlled ventilation (FCV) during cardiac
      surgery requiring cardiopulmonary bypass. Previous preclinical trials have already shown
      improved oxygenation and CO2 removal within a significantly reduced respiratory minute volume
      as an expression of more efficient gas exchange with FCV compared to volume controlled
      ventilation (VCV). Preliminary data of our own animal study comparing individualized FCV by
      compliance guided pressure settings with state-of-the-art low tidal volume pressure
      controlled ventilation (PCV) confirmed previous findings with a significantly improved
      oxygenation by 20% while reducing respiratory minute volume. We therefore assume that FCV may
      be a more lung protective ventilation method.

      Open heart surgery requires bridging of the heart and lung function with a cardiopulmonary
      bypass (CPB) performed by a heart-lung machine. During this time the lung is most frequently
      not ventilated at all and lies collapsed in the chest for several hours. After weaning from
      CPB, the lungs must be recruited and ensure sufficient gas exchange of the blood. Not
      surprisingly, the incidence of postoperative pulmonary complications (PPC) at 20-30% is
      comparatively high after cardiac surgery and is the leading cause of perioperative mortality.
      Based on previous trials we expect improved oxygenation and thus arterial partial pressure of
      oxygen (pO2) is the main primary outcome parameter of this study. Furthermore, we expect
      improved recruitment of lung tissue due to controlled expiratory flow in FCV without the need
      of recruitment maneuvers, which may cause deleterious effects on lung tissue. Thus, lung
      tissue aeration assessed by Hounsfield units analyses of a postoperative computed tomography
      will be a secondary outcome parameter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>controlled, prospective</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Horowitz Index</measure>
    <time_frame>15 minutes after chest closure</time_frame>
    <description>arterial partial pressure of Oxygen (paO2) / fraction of inspired Oxygen (FiO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung tissue aeration</measure>
    <time_frame>immediately postoperative</time_frame>
    <description>Lung tissue aeration assessed by Hounsfield units analysis of computed tomography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Respiration; Artificial</condition>
  <condition>Positive-Pressure Respiration</condition>
  <arm_group>
    <arm_group_label>FCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during cardiac surgery until admission to postoperative ICU. Individualisation will be established by compliance guided end-expiratory and peak pressure setting, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during cardiac surgery until admission to postoperative ICU. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evone</intervention_name>
    <description>Airway ventilation device</description>
    <arm_group_label>FCV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Primus</intervention_name>
    <description>Airway ventilation device</description>
    <arm_group_label>PCV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects &gt;18 years

          -  Body weight &gt;40 kg

          -  Elective cardiac surgery with CPB and without ventilation during CPB

          -  American Society of Anaesthesiologists (ASA) risc classification I-IV

          -  Written informed consent

        Exclusion Criteria:

          -  Emergency surgery

          -  Female subjects known to be pregnant

          -  Known participation in another interventional clinical trial

          -  High risk cardiac surgery such as double valve surgery, re-cardiac surgery,
             intraoperative cardiac arrest or pre-existing high grade cardiomyopathy (ejection
             fraction &lt;30%)

          -  Closing operation field without chest closure due to hemodynamic instability

          -  Acute endocarditis under antibiotic treatment

          -  Minimal invasive valve surgery via thoracotomy (MIC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Martini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck, Dept. of Anaesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Spraider, MD</last_name>
    <phone>0043 512 504 80329</phone>
    <email>patrick.spraider@i-med.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judith Martini, MD</last_name>
    <phone>0043 512 504 80478</phone>
    <email>judith.martini@i-med.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Spraider, MD</last_name>
      <phone>0043 512 504 80329</phone>
      <email>patrick.spraider@i-med.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Judith Martini, MD</last_name>
      <phone>0043 512 504 80478</phone>
      <email>judith.martini@i-med.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Judith Martini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Spraider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Abram, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Mair, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Glodny, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Schmidt J, Wenzel C, Mahn M, Spassov S, Cristina Schmitz H, Borgmann S, Lin Z, Haberstroh J, Meckel S, Eiden S, Wirth S, Buerkle H, Schumann S. Improved lung recruitment and oxygenation during mandatory ventilation with a new expiratory ventilation assistance device: A controlled interventional trial in healthy pigs. Eur J Anaesthesiol. 2018 Oct;35(10):736-744. doi: 10.1097/EJA.0000000000000819.</citation>
    <PMID>29734208</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>flow controlled ventilation</keyword>
  <keyword>pressure controlled ventilation</keyword>
  <keyword>cardiac surgery</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

